Cargando…

Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function

OBJECTIVE: To assess the efficacy of three-dimensional conformal radiotherapy (3D-CRT) combined with GT chemotherapy (gemcitabine+docetaxel) in the treatment of advanced bladder cancer and its influence on inflammatory factors and immune function. METHODS: A total of 42 elderly patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianwei, Liu, Min, Sun, Pengyu, Zhao, Wanli, Song, Miaomiao, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023190/
https://www.ncbi.nlm.nih.gov/pubmed/35466316
http://dx.doi.org/10.1155/2022/9347218
_version_ 1784690283283218432
author Li, Jianwei
Liu, Min
Sun, Pengyu
Zhao, Wanli
Song, Miaomiao
Liu, Yang
author_facet Li, Jianwei
Liu, Min
Sun, Pengyu
Zhao, Wanli
Song, Miaomiao
Liu, Yang
author_sort Li, Jianwei
collection PubMed
description OBJECTIVE: To assess the efficacy of three-dimensional conformal radiotherapy (3D-CRT) combined with GT chemotherapy (gemcitabine+docetaxel) in the treatment of advanced bladder cancer and its influence on inflammatory factors and immune function. METHODS: A total of 42 elderly patients with advanced bladder cancer who were admitted to our hospital from January 2019 to January 2020 were included and assigned to the GT group (21 cases) receiving GT chemotherapy and combination group (21 cases) given 3D-CRT combined with GT chemotherapy. The clinical efficacy, immune function, inflammatory factors, tumor markers, urinary angiogenesis molecules before and after treatment, 1-year survival rate, 2-year survival rate, and incidence of adverse reactions of the two groups were compared. SPSS 22.0 statistical software was used for data processing and analysis. RESULTS: The combination group had 5 cases of CR, 12 cases of PR, 3 cases of SD, and 1 case of PD, with an ORR of 80.95% (17/21), which was remarkably higher than the ORR of 57.14% (12/21) in the GT group which had 3 cases of CR, 9 cases of PR, 5 cases of SD, and 4 cases of PD (P < 0.05). The 1-year survival rate of the combination group was 76.19% (16/21), and the 2-year survival rate was 47.62% (10/21), which were higher than the 1-year survival rate of 47.62% (10/21) and 2-year survival rate of 19.05% (4/21) in the GT group (P < 0.05). The two groups presented similar results in terms of adverse reactions rate (P > 0.05). After treatment, the combination group obtained significantly lower levels of urinary bladder cancer antigen (UBC), nuclear matrix protein-22 (NMP-22), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) than the GT group (P < 0.05). The CD3+, CD4+, and CD4+/CD8+ levels of the two groups of patients were lower than those before treatment (P < 0.05), but no statistical difference was observed between the two groups after treatment (P > 0.05). The levels of interleukin-6 (IL-6) and interferon-γ (IFN-γ) of the two groups witnessed a decline after treatment, with lower results in the combination group as compared to the control group (P < 0.05). Before treatment, no significant difference in the Generic Quality of Life Inventory-74 (GQOLI-74) score between the two groups was found (P > 0.05). After treatment, the combination group had higher GQOLI-74 scores than the GT group (P < 0.05). CONCLUSION: 3D-CRT combined with GT chemotherapy yields a significant effect on the treatment of elderly advanced bladder cancer by effectively protecting immune function, mitigating inflammation, inhibiting tumor marker levels and the expression of angiogenic molecules, and improving patients' survival.
format Online
Article
Text
id pubmed-9023190
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90231902022-04-22 Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function Li, Jianwei Liu, Min Sun, Pengyu Zhao, Wanli Song, Miaomiao Liu, Yang J Oncol Research Article OBJECTIVE: To assess the efficacy of three-dimensional conformal radiotherapy (3D-CRT) combined with GT chemotherapy (gemcitabine+docetaxel) in the treatment of advanced bladder cancer and its influence on inflammatory factors and immune function. METHODS: A total of 42 elderly patients with advanced bladder cancer who were admitted to our hospital from January 2019 to January 2020 were included and assigned to the GT group (21 cases) receiving GT chemotherapy and combination group (21 cases) given 3D-CRT combined with GT chemotherapy. The clinical efficacy, immune function, inflammatory factors, tumor markers, urinary angiogenesis molecules before and after treatment, 1-year survival rate, 2-year survival rate, and incidence of adverse reactions of the two groups were compared. SPSS 22.0 statistical software was used for data processing and analysis. RESULTS: The combination group had 5 cases of CR, 12 cases of PR, 3 cases of SD, and 1 case of PD, with an ORR of 80.95% (17/21), which was remarkably higher than the ORR of 57.14% (12/21) in the GT group which had 3 cases of CR, 9 cases of PR, 5 cases of SD, and 4 cases of PD (P < 0.05). The 1-year survival rate of the combination group was 76.19% (16/21), and the 2-year survival rate was 47.62% (10/21), which were higher than the 1-year survival rate of 47.62% (10/21) and 2-year survival rate of 19.05% (4/21) in the GT group (P < 0.05). The two groups presented similar results in terms of adverse reactions rate (P > 0.05). After treatment, the combination group obtained significantly lower levels of urinary bladder cancer antigen (UBC), nuclear matrix protein-22 (NMP-22), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) than the GT group (P < 0.05). The CD3+, CD4+, and CD4+/CD8+ levels of the two groups of patients were lower than those before treatment (P < 0.05), but no statistical difference was observed between the two groups after treatment (P > 0.05). The levels of interleukin-6 (IL-6) and interferon-γ (IFN-γ) of the two groups witnessed a decline after treatment, with lower results in the combination group as compared to the control group (P < 0.05). Before treatment, no significant difference in the Generic Quality of Life Inventory-74 (GQOLI-74) score between the two groups was found (P > 0.05). After treatment, the combination group had higher GQOLI-74 scores than the GT group (P < 0.05). CONCLUSION: 3D-CRT combined with GT chemotherapy yields a significant effect on the treatment of elderly advanced bladder cancer by effectively protecting immune function, mitigating inflammation, inhibiting tumor marker levels and the expression of angiogenic molecules, and improving patients' survival. Hindawi 2022-04-14 /pmc/articles/PMC9023190/ /pubmed/35466316 http://dx.doi.org/10.1155/2022/9347218 Text en Copyright © 2022 Jianwei Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Jianwei
Liu, Min
Sun, Pengyu
Zhao, Wanli
Song, Miaomiao
Liu, Yang
Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function
title Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function
title_full Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function
title_fullStr Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function
title_full_unstemmed Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function
title_short Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function
title_sort three-dimensional conformal radiotherapy combined with gemcitabine and docetaxel in the treatment of advanced bladder cancer and its effects on inflammatory factors and immune function
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023190/
https://www.ncbi.nlm.nih.gov/pubmed/35466316
http://dx.doi.org/10.1155/2022/9347218
work_keys_str_mv AT lijianwei threedimensionalconformalradiotherapycombinedwithgemcitabineanddocetaxelinthetreatmentofadvancedbladdercanceranditseffectsoninflammatoryfactorsandimmunefunction
AT liumin threedimensionalconformalradiotherapycombinedwithgemcitabineanddocetaxelinthetreatmentofadvancedbladdercanceranditseffectsoninflammatoryfactorsandimmunefunction
AT sunpengyu threedimensionalconformalradiotherapycombinedwithgemcitabineanddocetaxelinthetreatmentofadvancedbladdercanceranditseffectsoninflammatoryfactorsandimmunefunction
AT zhaowanli threedimensionalconformalradiotherapycombinedwithgemcitabineanddocetaxelinthetreatmentofadvancedbladdercanceranditseffectsoninflammatoryfactorsandimmunefunction
AT songmiaomiao threedimensionalconformalradiotherapycombinedwithgemcitabineanddocetaxelinthetreatmentofadvancedbladdercanceranditseffectsoninflammatoryfactorsandimmunefunction
AT liuyang threedimensionalconformalradiotherapycombinedwithgemcitabineanddocetaxelinthetreatmentofadvancedbladdercanceranditseffectsoninflammatoryfactorsandimmunefunction